Amgen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Is Amgen Inc. (AMGN) A Good Stock To Buy Now?

AI-generated analysis

📈 Amgen stock was trading at $344.57 with a forward P/E of 15.48 as of June 9, 2026.

🛡️ The company's biosimilars platform has evolved into a meaningful profit contributor that monetizes legacy asset erosion.

💊 Repatha benefits from improving reimbursement dynamics and expanding cardiovascular risk awareness.

🌬️ TEZSPIRE adds growth potential in the underpenetrated severe asthma biologics market.

💰 Robust free cash flow generation allows Amgen to service debt while funding innovation.

📉 Management's mid-single-digit revenue guidance is viewed as conservative relative to pipeline optionality.

🏛️ The Horizon acquisition has elevated leverage, but cash flows remain sufficient for operations.

📊 Hedge fund portfolios holding AMGN decreased from 70 in Q1 to 65 by the end of the first quarter.

🔍 Analysts believe market sentiment currently lags behind Amgen's underlying fundamentals and earnings power.

Bullish Signals
  • Amgen's biosimilars platform has evolved into a meaningful profit contributor, leveraging decades of manufacturing expertise to create a durable barrier to entry.
  • Improving reimbursement dynamics for Repatha and expanding cardiovascular risk awareness are reinforcing demand for its LDL-lowering therapies.
  • TEZSPIRE represents an underappreciated growth vector in severe asthma where biologics remain underpenetrated.
  • Amgen's robust free cash flow generation is sufficient to comfortably service debt while still funding innovation and shareholder returns.
  • Management's mid-single-digit revenue growth trajectory appears conservative relative to pipeline optionality, suggesting embedded upside to consensus expectations.
  • The company possesses a biosimilars franchise that monetizes rather than competes against biologic erosion from legacy assets.
Risk Factors
  • Amgen is facing a widely acknowledged loss-of-exclusivity (LOE) cliff with legacy assets such as Enbrel already in decline.
  • Otezla is currently under competitive pressure from the market.
  • The Horizon acquisition has elevated the company's leverage levels.
  • Hedge fund interest has declined, with portfolios holding AMGN dropping from 70 to 65 between Q1 and the end of the first quarter.
Full Analysis
This article presents a bullish investment thesis on Amgen Inc. (AMGN), noting the stock was trading at $344.57 as of June 9, 2026, with trailing and forward P/E ratios of 23.98 and 15.48 respectively. The core argument suggests that while the company faces a loss-of-exclusivity (LOE) cliff from legacy assets like Enbrel, the market underappreciates the strength and diversification of its replacement engine. The bullish case highlights Amgen's evolved biosimilars platform as a meaningful profit contributor that leverages decades of manufacturing expertise to create a durable barrier to entry. Additionally, improving reimbursement dynamics for Repatha and the growth potential of TEZSPIRE in severe asthma are cited as underappreciated growth vectors that reinforce demand despite competitive pressures. Despite elevated leverage from the Horizon acquisition, Amgen's robust free cash flow generation is deemed sufficient to service debt while funding innovation and shareholder returns. Management's conservative mid-single-digit revenue growth trajectory is viewed as offering embedded upside relative to consensus expectations, creating a compelling risk-reward profile where sentiment lags fundamentals. The article concludes that Amgen offers a setup where earnings power is materially underappreciated, combining resilient cash flows with pipeline optionality beyond LOE headwinds. While the author notes hedge fund holdings have slightly declined and suggests AI stocks may offer higher returns, the primary focus remains on AMGN's specific financial resilience and strategic positioning.